3293

HSD17B3

hydroxysteroid (17-beta) dehydrogenase 3;HSD17B3;hydroxysteroid (17-beta) dehydrogenase 3

17-beta-HSD 3|17-beta-HSD3|17-beta-hydroxysteroid dehydrogenase type 3|short chain dehydrogenase/reductase family 12C member 2|short chain dehydrogenase/reductase family 12C, member 2|testicular 17-beta-hydroxysteroid dehydrogenase|testosterone 17-beta-de

9q22

protein-coding

Androgen receptor and androgen metabolizing enzymes, 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5) and 5alpha-reductase1 (5alpha1), are frequently detected in primary tumor of breast cancer, but their status in metastatic lymph nodes has not been examined. The biological role of androgen in breast cancer and its metastatic process also remain unknown. In this study, we used immunohistochemistry to localize the expression of androgen receptor, 17betaHSD5, and 5alpha1 in primary tumors and paired metastatic lymph nodes and correlated the findings with clinicopathologic factors of individual patients. Approximately 70% of primary tumors and paired metastatic lymph nodes expressed androgen receptor, with significant correlation between both lesions. However, 17betaHSD5 and 5alpha1 immunoreactivity was decreased in metastatic lymph nodes. Alone or in tandem with androgen receptor, 5alpha1 was associated with significantly lower Ki-67 index, lower pathologic grade, and higher estrogen receptor positivity, but androgen receptor/5alpha1 double positivity in lymph nodes was associated with larger lymph node metastasis and higher TNM stage. In conclusion, androgen receptor immunoreactivity remained stable during the process of metastasis, whereas androgen-metabolizing enzymes decreased. Although results of our study and previous reports imply additional roles of androgen metabolism in the metastasis process, especially conversion by 5alpha1, there may be divergence between its effects on primary tumor and those in metastatic lymph nodes.